AP240A - Synergistic therapeutic compositions of renin inhibitor and angiotensins and methods. - Google Patents

Synergistic therapeutic compositions of renin inhibitor and angiotensins and methods. Download PDF

Info

Publication number: AP240A
Authority: AP; ARIPO
Prior art keywords: amount; angiotensin; inhibitor; antagonist; pharmaceutical composition
Prior art date: 1990-05-11

Application number

APAP/P/1991/000258A

Other languages

English (en)

Other versions

AP9100258A0 (en

Inventor

Anthony Andrea Fossa

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-11

Filing date

1991-05-06

Publication date

1993-02-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-05-06 Application filed by Pfizer filed Critical Pfizer

1991-07-31 Publication of AP9100258A0 publication Critical patent/AP9100258A0/xx

1993-02-18 Application granted granted Critical

1993-02-18 Publication of AP240A publication Critical patent/AP240A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 41
238000000034 method Methods 0.000 title claims abstract description 36
239000002461 renin inhibitor Substances 0.000 title claims description 94
229940086526 renin-inhibitors Drugs 0.000 title claims description 94
230000001225 therapeutic effect Effects 0.000 title claims description 58
230000002195 synergetic effect Effects 0.000 title claims description 27
108010064733 Angiotensins Proteins 0.000 title claims 10
102000015427 Angiotensins Human genes 0.000 title claims 10
239000002416 angiotensin derivative Substances 0.000 title 1
239000005541 ACE inhibitor Substances 0.000 claims description 81
239000005557 antagonist Substances 0.000 claims description 73
241000124008 Mammalia Species 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 34
239000008194 pharmaceutical composition Substances 0.000 claims description 31
229960000830 captopril Drugs 0.000 claims description 28
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 28
239000003112 inhibitor Substances 0.000 claims description 17
229940123413 Angiotensin II antagonist Drugs 0.000 claims description 15
239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 15
229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 14
239000003085 diluting agent Substances 0.000 claims description 13
229940124597 therapeutic agent Drugs 0.000 claims description 12
101800000734 Angiotensin-1 Proteins 0.000 claims description 9
102400000344 Angiotensin-1 Human genes 0.000 claims description 9
108010061435 Enalapril Proteins 0.000 claims description 7
229960000873 enalapril Drugs 0.000 claims description 7
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
108010007859 Lisinopril Proteins 0.000 claims description 6
229960002394 lisinopril Drugs 0.000 claims description 6
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 6
229960003401 ramipril Drugs 0.000 claims description 6
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 6
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 3
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 3
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims description 3
UVZMNGNFERVGRC-UHFFFAOYSA-N 4-cyclohexylbutanoic acid Chemical compound OC(=O)CCCC1CCCCC1 UVZMNGNFERVGRC-UHFFFAOYSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
230000002301 combined effect Effects 0.000 claims 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 60
206010007559 Cardiac failure congestive Diseases 0.000 description 17
206010019280 Heart failures Diseases 0.000 description 17
230000036772 blood pressure Effects 0.000 description 15
150000001875 compounds Chemical class 0.000 description 12
241001465754 Metazoa Species 0.000 description 10
230000004872 arterial blood pressure Effects 0.000 description 7
231100000673 dose–response relationship Toxicity 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000011260 co-administration Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000012935 Averaging Methods 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
108090000783 Renin Proteins 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000004531 blood pressure lowering effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
230000001077 hypotensive effect Effects 0.000 description 3
-1 isopropyl ester Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229960003883 furosemide Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
235000015424 sodium Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
235000002917 Fraxinus ornus Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
229940047766 co-trimoxazole Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940063711 lasix Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000014659 low sodium diet Nutrition 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052573 porcelain Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000005737 synergistic response Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000005303 weighing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

APAP/P/1991/000258A 1990-05-11 1991-05-06 Synergistic therapeutic compositions of renin inhibitor and angiotensins and methods. AP240A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52236090A	1990-05-11	1990-05-11

Publications (2)

Publication Number	Publication Date
AP9100258A0 AP9100258A0 (en)	1991-07-31
AP240A true AP240A (en)	1993-02-18

Family

ID=24080550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1991/000258A AP240A (en)	1990-05-11	1991-05-06	Synergistic therapeutic compositions of renin inhibitor and angiotensins and methods.

Country Status (33)

Country	Link
US (2)	US6716875B1 (de)
EP (1)	EP0527879B1 (de)
JP (2)	JPH0729938B2 (de)
KR (1)	KR970005839B1 (de)
CN (7)	CN101156949A (de)
AP (1)	AP240A (de)
AT (1)	ATE148632T1 (de)
AU (1)	AU653724B2 (de)
BG (1)	BG61831B1 (de)
BR (1)	BR9106438A (de)
CA (1)	CA2081564C (de)
DE (1)	DE69124598T2 (de)
DK (1)	DK0527879T3 (de)
EG (1)	EG19648A (de)
ES (1)	ES2097208T3 (de)
GR (1)	GR3022997T3 (de)
GT (1)	GT199100032A (de)
HU (1)	HU227346B1 (de)
IE (1)	IE911592A1 (de)
IL (1)	IL98055A (de)
IS (1)	IS2042B (de)
MA (1)	MA22150A1 (de)
MY (1)	MY114347A (de)
NO (1)	NO924321L (de)
NZ (1)	NZ238118A (de)
PE (1)	PE30891A1 (de)
PT (1)	PT97615B (de)
RO (1)	RO115786B1 (de)
RU (1)	RU2147875C1 (de)
TW (1)	TW203553B (de)
WO (1)	WO1991017771A1 (de)
YU (1)	YU49094B (de)
ZA (1)	ZA913539B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0527879T3 (da) *	1990-05-11	1997-07-14	Pfizer	Synergistiske terapeutiske præparater og fremgangsmåder.
EP0629408A1 (de) *	1993-06-16	1994-12-21	LABORATOIRES MERCK, SHARP & DOHME-CHIBRET	Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
DE4340437C1 (de) *	1993-11-27	1995-05-24	Karla Dr Lehmann	Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
CZ313897A3 (cs) *	1995-04-07	1998-01-14	Novartis Ag	Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JPH11508894A (ja) *	1995-06-30	1999-08-03	メルクエンドカンパニーインコーポレーテッド	Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
EP0914158B2 (de) *	1996-04-05	2006-01-25	Takeda Chemical Industries, Ltd.	Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
US6087386A (en) *	1996-06-24	2000-07-11	Merck & Co., Inc.	Composition of enalapril and losartan
JP2000513356A (ja) *	1996-06-24	2000-10-10	メルクエンドカンパニーインコーポレーテッド	エナラプリルとロサルタンの組成物
WO1999015643A2 (en) *	1997-09-25	1999-04-01	University Of Florida	ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
EP1047450B1 (de) *	1997-12-23	2002-10-02	Warner-Lambert Company	Ace hemmer/matrix metalloproteinase hemmer-arzneimittelkombinationen
US6087343A (en) *	1998-09-14	2000-07-11	University Of Florida	Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) *	1999-06-11	2002-05-14	Pfizer Inc.	Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2490811A1 (en) *	2002-06-28	2004-01-08	Novartis Ag	Use of organic compounds
CA2811272C (en)	2003-04-08	2016-12-20	Progenics Pharmaceuticals, Inc.	Pharmaceutical formulations containing methylnaltrexone
US20040265238A1 (en)	2003-06-27	2004-12-30	Imtiaz Chaudry	Inhalable formulations for treating pulmonary hypertension and methods of using same
ES2384637T3 (es) *	2004-10-08	2012-07-10	Novartis Ag	Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
ES2714198T3 (es) *	2005-03-07	2019-05-27	Univ Chicago	Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en)	2005-03-07	2013-08-27	The University Of Chicago	Use of opioid antagonists
US8524731B2 (en)	2005-03-07	2013-09-03	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en)	2005-03-07	2017-05-30	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es)	2005-05-25	2007-11-14	Progenics Pharm Inc	SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es)	2005-05-25	2007-11-28	Progenics Pharm Inc	Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) *	2006-09-08	2008-04-16	Wyeth Corp	Dry powder compound formulations and uses thereof
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2565195B1 (de)	2007-03-29	2015-05-06	Wyeth LLC	Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
JP2010522756A (ja)	2007-03-29	2010-07-08	プロジェニックスファーマシューティカルズ，インコーポレーテッド	結晶形およびその使用
PL2137191T3 (pl)	2007-03-29	2016-12-30		Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en)	2008-02-06	2014-02-13	Progenics Pharmaceuticals, Inc.	Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en)	2008-09-30	2017-04-25	Wyeth	Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) *	2011-11-24	2012-04-25	西北农林科技大学	一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) *	2021-11-17	2024-02-02	山东省科学院生物研究所	一种多功能西洋参水解肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4880804A (en) *	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
US4895834A (en) *	1986-12-15	1990-01-23	Warner-Lambert Company	Renin inhibitors III

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US324377A (en) *		1885-08-18		Roller-skate
US4046889A (en) *	1976-02-13	1977-09-06	E. R. Squibb & Sons, Inc.	Azetidine-2-carboxylic acid derivatives
IL58849A (en) *	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en)	1986-06-20	1988-06-07	Schering Corporation	Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
DE3633861A1 (de) *	1986-10-04	1988-04-07	Thomae Gmbh Dr K	Neue imidazo-benzoxazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4814342A (en)	1986-10-31	1989-03-21	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
US4874759A (en) *	1987-01-23	1989-10-17	Yoshitomi Pharmaceutical Industries, Ltd.	5-Hydroxyindole-3-carboxylic acid amide compounds, pharmaceutical compositions and use
US4962105A (en)	1987-10-19	1990-10-09	Ciba-Geigy Corporation	Potentiation of antihypertensive effect of ace inhibitors
US5015651A (en)	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en)	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IL91780A (en)	1988-10-04	1995-08-31	Abbott Lab	History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
DK0527879T3 (da) *	1990-05-11	1997-07-14	Pfizer	Synergistiske terapeutiske præparater og fremgangsmåder.

1991
- 1991-04-22 DK DK91909382.3T patent/DK0527879T3/da active
- 1991-04-22 HU HU9203522A patent/HU227346B1/hu unknown
- 1991-04-22 AT AT91909382T patent/ATE148632T1/de not_active IP Right Cessation
- 1991-04-22 ES ES91909382T patent/ES2097208T3/es not_active Expired - Lifetime
- 1991-04-22 CA CA002081564A patent/CA2081564C/en not_active Expired - Lifetime
- 1991-04-22 BR BR919106438A patent/BR9106438A/pt not_active Application Discontinuation
- 1991-04-22 AU AU78591/91A patent/AU653724B2/en not_active Expired
- 1991-04-22 KR KR1019920702805A patent/KR970005839B1/ko not_active Expired - Lifetime
- 1991-04-22 RU RU92016534A patent/RU2147875C1/ru active
- 1991-04-22 EP EP91909382A patent/EP0527879B1/de not_active Expired - Lifetime
- 1991-04-22 JP JP3508991A patent/JPH0729938B2/ja not_active Expired - Lifetime
- 1991-04-22 WO PCT/US1991/002733 patent/WO1991017771A1/en not_active Ceased
- 1991-04-22 DE DE69124598T patent/DE69124598T2/de not_active Expired - Lifetime
- 1991-04-22 RO RO92-01405A patent/RO115786B1/ro unknown
- 1991-05-01 TW TW080103439A patent/TW203553B/zh not_active IP Right Cessation
- 1991-05-03 IL IL9805591A patent/IL98055A/en not_active IP Right Cessation
- 1991-05-06 AP APAP/P/1991/000258A patent/AP240A/en active
- 1991-05-08 EG EG27891A patent/EG19648A/xx active
- 1991-05-08 MA MA22420A patent/MA22150A1/fr unknown
- 1991-05-09 PT PT97615A patent/PT97615B/pt not_active IP Right Cessation
- 1991-05-10 ZA ZA913539A patent/ZA913539B/xx unknown
- 1991-05-10 CN CNA2007101867127A patent/CN101156949A/zh active Pending
- 1991-05-10 GT GT199100032A patent/GT199100032A/es unknown
- 1991-05-10 IE IE159291A patent/IE911592A1/en not_active IP Right Cessation
- 1991-05-10 IS IS3703A patent/IS2042B/is unknown
- 1991-05-10 CN CNB2003101199156A patent/CN100358578C/zh not_active Expired - Lifetime
- 1991-05-10 CN CN2005100035730A patent/CN1824315B/zh not_active Expired - Lifetime
- 1991-05-10 NZ NZ238118A patent/NZ238118A/en unknown
- 1991-05-10 CN CNA2006101018493A patent/CN1915428A/zh active Pending
- 1991-05-10 CN CNA2006100934632A patent/CN1879884A/zh active Pending
- 1991-05-10 PE PE1991185538A patent/PE30891A1/es unknown
- 1991-05-10 CN CN91103177A patent/CN1065140C/zh not_active Expired - Lifetime
- 1991-05-10 YU YU81991A patent/YU49094B/sh unknown
- 1991-05-10 MY MYPI91000798A patent/MY114347A/en unknown
1992
- 1992-11-10 NO NO92924321A patent/NO924321L/no unknown
- 1992-11-10 BG BG97068A patent/BG61831B1/bg unknown
1994
- 1994-06-27 JP JP6144998A patent/JP2635291B2/ja not_active Expired - Lifetime
1995
- 1995-06-05 US US08/465,660 patent/US6716875B1/en not_active Expired - Lifetime
- 1995-06-05 US US08/463,878 patent/US6900234B1/en not_active Expired - Lifetime
1997
- 1997-04-01 GR GR970400671T patent/GR3022997T3/el unknown
2000
- 2000-04-29 CN CN00108186A patent/CN1307901A/zh active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4895834A (en) *	1986-12-15	1990-01-23	Warner-Lambert Company	Renin inhibitors III
US4880804A (en) *	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 104, 103835, (1984) *
CHEMICAL ABSTRACTS, Vol. 107, 1910506, (1987) *
CHEMICAL ABSTRACTS, Vol. 98, 10933u, (1983) *

Also Published As

Publication number	Publication date
US6900234B1 (en)	2005-05-31
ATE148632T1 (de)	1997-02-15
JPH0729938B2 (ja)	1995-04-05
PT97615B (pt)	1998-08-31
MA22150A1 (fr)	1991-12-31
YU81991A (sh)	1994-06-24
CN1824315B (zh)	2011-01-12
JPH05505618A (ja)	1993-08-19
WO1991017771A1 (en)	1991-11-28
BG61831B1 (bg)	1998-07-31
IL98055A (en)	1996-10-31
ZA913539B (en)	1992-12-30
CA2081564C (en)	1998-02-03
CN1824315A (zh)	2006-08-30
PT97615A (pt)	1992-03-31
YU49094B (sh)	2003-12-31
TW203553B (de)	1993-04-11
AU7859191A (en)	1991-12-10
ES2097208T3 (es)	1997-04-01
CA2081564A1 (en)	1991-11-12
CN1502370A (zh)	2004-06-09
NO924321L (no)	1993-01-08
DK0527879T3 (da)	1997-07-14
AP9100258A0 (en)	1991-07-31
GT199100032A (es)	1992-10-31
RU2147875C1 (ru)	2000-04-27
CN1056426A (zh)	1991-11-27
CN1307901A (zh)	2001-08-15
HU9203522D0 (en)	1993-01-28
NZ238118A (en)	1997-06-24
HUT62804A (en)	1993-06-28
IE911592A1 (en)	1991-11-20
CN1879884A (zh)	2006-12-20
CN1065140C (zh)	2001-05-02
BG97068A (bg)	1993-12-24
CN101156949A (zh)	2008-04-09
EP0527879B1 (de)	1997-02-05
BR9106438A (pt)	1993-05-18
JP2635291B2 (ja)	1997-07-30
HU227346B1 (en)	2011-04-28
CN1915428A (zh)	2007-02-21
HK1094148A1 (en)	2007-03-23
JPH0748280A (ja)	1995-02-21
IS3703A7 (is)	1991-11-12
US6716875B1 (en)	2004-04-06
DE69124598D1 (de)	1997-03-20
EG19648A (en)	1995-09-30
CN100358578C (zh)	2008-01-02
IS2042B (is)	2005-09-15
GR3022997T3 (en)	1997-07-30
RO115786B1 (ro)	2000-06-30
KR970005839B1 (ko)	1997-04-21
IL98055A0 (en)	1992-06-21
NO924321D0 (no)	1992-11-10
DE69124598T2 (de)	1997-05-28
MY114347A (en)	2002-10-31
AU653724B2 (en)	1994-10-13
PE30891A1 (es)	1991-11-27
EP0527879A1 (de)	1993-02-24

Publication	Publication Date	Title
AP240A (en)	1993-02-18	Synergistic therapeutic compositions of renin inhibitor and angiotensins and methods.
US5821232A (en)	1998-10-13	Synergistic therapeutic compositions and methods
US20120053222A1 (en)	2012-03-01	Novel Metabolic Disease Therapy
EP0498361A2 (de)	1992-08-12	Kombination von einem Angiotensin II Antagonist oder einem Renininhibitor mit einem neutralen Endopeptidasehemmer
Feuerstein et al.	1999	An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis
SK14962001A3 (sk)	2002-06-04	Farmaceutický prípravok obsahujúci inhibítor trombínu s nízkou molekulovou hmotnosťou a jeho prekurzor
Karagiannis et al.	2010	The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis
KR20010099628A (ko)	2001-11-09	복합 장기장애에 대한 예방 및 치료제
CZ292946B6 (cs)	2004-01-14	Farmaceutický prostředek pro snížení krevního tlaku a léčení městnavého srdečního selhání a použití
HK1094148B (en)	2011-09-09	Synergistic therapeutic compositions and methods
HK1115536A (en)	2008-12-05	A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug